BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 34407787)

  • 1. Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells.
    Moon SY; Lee H; Kim S; Hong JH; Chun SH; Lee HY; Kang K; Kim HS; Won HS; Ko YH
    BMC Cancer; 2021 Aug; 21(1):931. PubMed ID: 34407787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
    Guest SK; Ribas R; Pancholi S; Nikitorowicz-Buniak J; Simigdala N; Dowsett M; Johnston SR; Martin LA
    PLoS One; 2016; 11(6):e0157397. PubMed ID: 27308830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of methionine adenosyltransferase 2A in tamoxifen-resistant breast cancer cells.
    Phuong NT; Kim SK; Im JH; Yang JW; Choi MC; Lim SC; Lee KY; Kim YM; Yoon JH; Kang KW
    Oncotarget; 2016 Mar; 7(12):13902-16. PubMed ID: 26418898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
    Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
    FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer.
    Giannoudis A; Malki MI; Rudraraju B; Mohhamed H; Menon S; Liloglou T; Ali S; Carroll JS; Palmieri C
    Breast Cancer Res; 2020 Nov; 22(1):126. PubMed ID: 33198803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
    Jordan NJ; Dutkowski CM; Barrow D; Mottram HJ; Hutcheson IR; Nicholson RI; Guichard SM; Gee JM
    Breast Cancer Res; 2014 Jan; 16(1):R12. PubMed ID: 24457069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acquired resistance to endocrine treatments is associated with tumor-specific molecular changes in patient-derived luminal breast cancer xenografts.
    Cottu P; Bièche I; Assayag F; El Botty R; Chateau-Joubert S; Thuleau A; Bagarre T; Albaud B; Rapinat A; Gentien D; de la Grange P; Sibut V; Vacher S; Hatem R; Servely JL; Fontaine JJ; Decaudin D; Pierga JY; Roman-Roman S; Marangoni E
    Clin Cancer Res; 2014 Aug; 20(16):4314-25. PubMed ID: 24947930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer.
    Loh YN; Hedditch EL; Baker LA; Jary E; Ward RL; Ford CE
    BMC Cancer; 2013 Apr; 13():174. PubMed ID: 23547709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of the CD59 Glycoprotein Precursor is Upregulated in an Estrogen Receptor-alpha (ER-α)-Negative and a Tamoxifen-Resistant Breast Cancer Cell Line In Vitro.
    Xiong H; Jin X; You C
    Med Sci Monit; 2018 Nov; 24():7883-7890. PubMed ID: 30391994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of TMEM47 Induces Tamoxifen Resistance in Human Breast Cancer Cells.
    Men X; Su M; Ma J; Mou Y; Dai P; Chen C; Cheng XA
    Technol Cancer Res Treat; 2021; 20():15330338211004916. PubMed ID: 33745390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-148a and miR-152 reduce tamoxifen resistance in ER+ breast cancer via downregulating ALCAM.
    Chen MJ; Cheng YM; Chen CC; Chen YC; Shen CJ
    Biochem Biophys Res Commun; 2017 Feb; 483(2):840-846. PubMed ID: 28063929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan.
    Hiscox S; Baruha B; Smith C; Bellerby R; Goddard L; Jordan N; Poghosyan Z; Nicholson RI; Barrett-Lee P; Gee J
    BMC Cancer; 2012 Oct; 12():458. PubMed ID: 23039365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Essential role of Notch4/STAT3 signaling in epithelial-mesenchymal transition of tamoxifen-resistant human breast cancer.
    Bui QT; Im JH; Jeong SB; Kim YM; Lim SC; Kim B; Kang KW
    Cancer Lett; 2017 Apr; 390():115-125. PubMed ID: 28108315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nogo-B receptor increases the resistance to tamoxifen in estrogen receptor-positive breast cancer cells.
    Gao P; Wang X; Jin Y; Hu W; Duan Y; Shi A; Du Y; Song D; Yang M; Li S; Han B; Zhao G; Zhang H; Fan Z; Miao QR
    Breast Cancer Res; 2018 Sep; 20(1):112. PubMed ID: 30208932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AhR ligand aminoflavone suppresses α6-integrin-Src-Akt signaling to attenuate tamoxifen resistance in breast cancer cells.
    Campbell PS; Mavingire N; Khan S; Rowland LK; Wooten JV; Opoku-Agyeman A; Guevara A; Soto U; Cavalli F; Loaiza-Pérez AI; Nagaraj G; Denham LJ; Adeoye O; Jenkins BD; Davis MB; Schiff R; Brantley EJ
    J Cell Physiol; 2018 Jan; 234(1):108-121. PubMed ID: 30076704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of BAG-1 expression alters the sensitivity of breast cancer cells to tamoxifen.
    Liu H; Lu S; Gu L; Gao Y; Wang T; Zhao J; Rao J; Chen J; Hao X; Tang SC
    Cell Physiol Biochem; 2014; 33(2):365-74. PubMed ID: 24557447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IGFBP-1 Expression Promotes Tamoxifen Resistance in Breast Cancer Cells via Erk Pathway Activation.
    Zheng Y; Sowers JY; Houston KD
    Front Endocrinol (Lausanne); 2020; 11():233. PubMed ID: 32435229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased STAT1 signaling in endocrine-resistant breast cancer.
    Huang R; Faratian D; Sims AH; Wilson D; Thomas JS; Harrison DJ; Langdon SP
    PLoS One; 2014; 9(4):e94226. PubMed ID: 24728078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Essential Role of Polo-like Kinase 1 (Plk1) Oncogene in Tumor Growth and Metastasis of Tamoxifen-Resistant Breast Cancer.
    Jeong SB; Im JH; Yoon JH; Bui QT; Lim SC; Song JM; Shim Y; Yun J; Hong J; Kang KW
    Mol Cancer Ther; 2018 Apr; 17(4):825-837. PubMed ID: 29437878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effect of EGFR inhibitors on tamoxifen-resistant breast cancer cells.
    Kim S; Lee J; Oh SJ; Nam SJ; Lee JE
    Oncol Rep; 2015 Sep; 34(3):1613-9. PubMed ID: 26166014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.